1. Mesa CS, Niubó CE, González NL. Características histopatológicas de una reacción de aglutinación observada en pacientes psicóticos. IV Congreso Ibero-Americano de Anatomía Patológica. IV-CVHAP 2001 Comunicación-E-001; 2001.
2. DSM-IV. Manual diagnóstico y estadístico de los trastornos mentales. 4 ed. Barcelona: Masson; 1995.
3. Mesa CS. Schizophrenia: cytopathological diagnosis valuation scale. Carib Med J 1998; 60: 29-32.
4. Mesa CS. Estudios sobre una prueba biológica en la esquizofrenia. Revista Médica de Oriente deVenezuela 1993; 3: 15-18.
5. Xalabarder C. Abnormal thrombocytes in schizophrenia: electron microscopy observation. Agressologie 1973; 14: 275-279.
6. Kessler A, Shinitzky M, Kessler B. Number of platelet dense granules varies with age, schizophrenia and dementia. Dementia 1995; 6: 330-333.
7. Mesa CS. Estudio ultraestructural del lóbulo temporal y de la sangre periférica en pacientes esquizofrénicos. Rev Neurol 2001; 33: 619-623.
8. Levine J, Gutman J, Feraro R, Levy P, Kimhi R, Leykin I, et al. Side effect profile of azathioprine in the treatment of chronic schizophrenic patients. Neuropsychobiology 1997; 36: 172-176.
9. Shinitzky M, Deckmann M, Kessler A, Sirota P, Rabbs A, Elizur A. Platelet autoantibodies in dementia and schizophrenia. Possible implication for mental disorders. Ann N Y Acad Sci 1991; 621: 205-217.
10. Deckmann M, Mamillapalli R, Schechtman L, Shinitzky M. A conformational epitope which detects autoantibodies from schizophrenic patients. Clin Chim Acta 2002; 322: 91-8.
11. Govitrapong P, Mukda S, Turakitwanakan W, Dumrongphol H, Chindaduangratn C, Sanvarinda Y. Platelet serotonin transporter in schizophrenic patients with and without neuroleptic treatment. Neurochem Int 2002; 41: 209-16.
12. Kaiser R, Muller-Oerlinghausen B, Filler D, Tremblay PB, Berghofer A, Roots I, Brockmoller J. Correlation between serotonin uptake in human blood platelets with the 44-bp polymorphism and the 17-bp variable number of tandem repeat of the serotonin transporter. Am J Med Genet 2002; 114: 323-8.
13. Kaneda Y, Fujii A, Nagamine I. Platelet serotonin concentrations in medicated schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry 2001; 25: 983-92.
14. Govitrapong P, Chagkutip J, Turakitwanakan W, Srikiatkhachorn A.
Platelet 5-HT(2A) receptors in schizophrenic patients with and without neuroleptic treatment.Psychiatry Res 2000; 96: 41-50.
15. Modai I, Gibel A, Rauchverger B, Ritsner M, Klein E, Ben-Shachar D. Paroxetine binding in aggressive schizophrenic patients. Psychiatry Res 2000; 94: 77-81.
16. Du L, Bakish D, Lapierre YD, Ravindran AV, Hrdina PD. Association of polymorphism of serotonin 2A receptor gene with suicidal ideation in major depressive disorder. Am J Med Genet 2000; 96: 879-880.
17. Muck-Seler D, Pivac N, Jakovljevic M. Sex differences, season of birth and platelet 5-HT levels in schizophrenic patients. J Neural Transm 1999; 106: 337-347.
18. Muck-Seler D, Pivac N, Jakovljevic M, Brzovic. Platelet serotonin, plasma cortisol, and dexamethasone suppression test in schizophrenic patients. Biol Psychiatry 1999; 45: 1433-1439.
19. Rao ML, Hawellek B, Papassotiropoulos A, Deister A, Frahnert C. Upregulation of the platelet Serotonin2A receptor and low blood serotonin in suicidal psychiatric patients. Neuropsychobiology 1998; 38: 84-9.
20. Meszaros Z, Borcsiczky D, Mate M, Tarcali J, Tekes K, Magyar K. MAO inhibitory side effects of neuroleptics and platelet serotonin content in schizophrenic patients. J Neural Transm Suppl 1998; 52:79-85.
21. Jakovljevic M, Muck-Seler D, Pivac N, Crncevic Z. Platelet 5-HT and plasma cortisol concentrations after dexamethasone suppression test in patients with different time course of schizophrenia. Neuropsychobiology 1998; 37:142-145.
22. Borcsiczky D, Tekes K, Tarcali J, Meszaros Z, Faludi G, Mathe M, Magyar K. Platelet rich plasma serotonin content in patients suffering from different psychiatric disorders. Acta Physiol Hung 1996; 84: 403-404.
23. Jakovljevic M, Muck-Seler D, Pivac N, Ljubicic D, Bujas M, Dodig G. Seasonal influence on platelet 5-HT levels in patients with recurrent major depression and schizophrenia. Biol Psychiatry 1997; 41: 1028-1034.
24. Pivac N, Muck-Seler D, Jakovljevic M. Platelet 5-HT levels and hypothalamic-pituitary-adrenal axis activity in schizophrenic patients with positive and negative symptoms. Neuropsychobiology 1997; 36:19-21.
25. Muck-Seler D, Bujas M, Ljubic-Thibal V, Jakovljevic M. Effect of age on platelet 5-HT concentrations in healthy controls, depressed and schizophrenic patients. Neuropsychobiology 1996; 34: 201-203.
26. Iqbal N, van Praag HM. The role of serotonin in schizophrenia. EurNeuropsychopharmacol 1995; 5 Suppl: 11-23.
27. Arora RC, Meltzer HY. Effect of clozapine treatment on serotonin-2-receptor binding in the blood platelets of schizophrenic patients.
Neuropsychopharmacology 1994; 10: 109-114.
28. Pandey SC, Sharma RP, Janicak PG, Marks RC, Davis JM, Pandey GN. Platelet serotonin-2 receptors in schizophrenia: effects of illness and neuroleptic treatment. Psychiatry Res 1993; 48: 57-68.
29. Arora RC, Meltzer HY. Serotonin2 receptor binding in blood platelets of schizophrenic patients. Psychiatry Res 1993; 47: 111-119.
30. Brusov OS, Dikaia VI, Zlobina GP, Faktor MI, Pavlova OA, Bologov PV, et al. Specific aspects of thrombocyte system of serotonin in patients with different manifestations of schizoaffective psychosis. Zh Nevrol Psikhiatr Im S S Korsakova 2000; 100: 50-54.
31. Dean B, Sundram S, Hill C, Copolov DL. Platelet
3Hdopamine uptake is differentially affected by neuroleptic drug treatment in schizophrenia and schizophreniform disorder. Prog Neuropsychopharmacol Biol Psychiatry 1996; 20: 45-55.
32. Brusov OS, Panteleeva GP, Bondar' VV, Dikaia VI, Faktor MI, Zlobina GP, et al. A clinico-biological study of the thrombocyte serotonin-transport complex in therapeutically resistant patients with endogenous depression undergoing combined treatment. Vestn Ross Akad Med Nauk 1996; 4: 29-32.
33. Sarne Y, Mandel J, Goncalves MH, Brook S, Gafni M, Elizur A. Imipramine binding to blood platelets and aggressive behavior in offenders, schizophrenics and normal volunteers. Neuropsychobiology 1995; 31: 120-124.
34. Rabey JM, Lerner A, Sigal M, Graff E, Oberman Z.
3Hdopamine uptake by platelet storage granules in schizophrenia. Life Sci 1992; 50: 65-72.
35. Yamada S, Akita H, Kanazawa K, Ishida T, Hirata K, Ito K, et al. T102C polymorphism of the serotonin (5-HT) 2A receptor gene in patients with non-fatal acute myocardial infarction. Atherosclerosis 2000; 150: 143-148.
36. Yao JK, van Kammen DP, Moss HB, Sokulski DE. Decreased serotonergic responsivity in platelets of drug-free patients with schizophrenia. Psychiatry Res 1996; 63: 123-132.
37. Yao JK, van Kammen DP, Gurklis J, Peters JL. Platelet aggregation and dense granule secretion in schizophrenia. Psychiatry Res 1994; 54: 13-24.
38. Karege F, Schwald M, Cisse M. Postnatal developmental profile of brain-derived neurotrophic factor in rat brain and platelets. Neurosci Lett 2002; 328: 261-264.
39. Rosenfeld RD, Zeni L, Haniu M, Talvenheimo J, Radka SF, Bennett L, Miller JA, Welcher AA. Purification and identification of brain-derived neurotrophic factor from human serum. Protein Expr Purif 1995; 6: 465-471.
40. Radka SF, Holst PA, Fritsche M, Altar CA. Presence of brain-derived neurotrophic factor in brain and human and rat but not mouse serum detected by a sensitive and specific immunoassay. Brain Res 1996; 709: 122-301.
41. Fujimura H, Altar CA, Chen R, Nakamura T, Nakahashi T, Kambayashi J, et al. Brain-derived neurotrophic factor is stored in human platelets and released by agonist stimulation. Thromb Haemost 2002; 87: 728-734.
42. Toyooka K, Asama K, Watanabe Y, Muratake T, Takahashi M, Someya T, et al. Decreased levels of brain-derived neurotrophic factor in serum of chronic schizophrenic patients. Psychiatry Res 2002; 110: 249-257.
43. Karege F, Perret G, Bondolfi G, Schwald M, Bertschy G, Aubry JM. Decreased serum brain-derived neurotrophic factor levels in major depressed patients. Psychiatry Res 2002; 109: 143-148.
44. Nakahashi T, Fujimura H, Altar CA, Li J, Kambayashi J, Tandon NN, et al. Vascular endothelial cells synthesize and secrete brain-derived neurotrophic factor. FEBS Lett 2000; 470: 113-117.
45. Pliego-Rivero FB, Bayatti N, Giannakoulopoulos X, Glover V, Bradford HF, Stern G, et al. Brain-derived neurotrophic factor in human platelets. Biochem Pharmacol 1997; 54: 207-209.
46. Yamamoto H, Gurney ME. Human platelets contain brain-derived neurotrophic factor. J Neurosci 1990; 10: 3469-3478.
47. Beasley C, Cotter D, Everall I. An investigation of the Wnt-signalling pathway in the prefrontal cortex in schizophrenia, bipolar disorder and major depressive disorder. Schizophr Res 2002; 58: 63.
48. Kozlovsky N, Belmaker RH, Agam G. GSK-3 and the neurodevelopmental hypothesis of schizophrenia. Eur Neuropsychopharmacol 2002 ; 12: 13-25.
49. Kozlovsky N, Belmaker RH, Agam G. Low GSK-3 activity in frontal cortex of schizophrenic patients. Schizophr Res 2001; 52: 101-105.
50. Beasley C, Cotter D, Khan N, Pollard C, Sheppard P, Varndell I, et al. Glycogen synthase kinase-3beta immunoreactivity is reduced in the prefrontal cortex in schizophrenia. Neurosci Lett 2001; 302: 117-120.
51. Kozlovsky N, Belmaker RH, Agam G. Low GSK-3beta immunoreactivity in postmortem frontal cortex of schizophrenic patients. Am J Psychiatry 2000; 157: 831-833.
52. Yang SD, Yu JS, Lee TT, Yang CC, Ni MH, Yang YY. Dysfunction of protein kinase FA/GSK-3 alpha in lymphocytes of patients with schizophrenic disorder. J Cell Biochem 1995; 59: 108-116.
53. Idrisov IM. Enzyme activity and glycogen level of leukocytes of patients with schizophrenia in relation to the nature of depressive states. Zh Nevropatol Psikhiatr Im S S Korsakova 1988; 88: 106-109.
54. Schmitt A, Maras A, Petroianu G, Braus DF, Scheuer L, Gattaz WF. Effects of antipsychotic treatment on membrane phospholipid metabolism in schizophrenia. J Neural Transm 2001; 108: 1081-1091.
55. Schmitt A, Maras A, Braus DF, Petroianu G, Jatzko A, Gattaz WF. Antipsychotics and phospholipid metabolism in schizophrenia. Fortschr Neurol Psychiatr 2001; 69: 503-509.
56. Ripova D, Strunecka A, Nemcova V, Farska I. Phospholipids and calcium alterations in platelets of schizophrenic patients. Physiol Res 1997; 46: 59-68.
57. Yao JK, van Kammen DP, Gurklis JA. Abnormal incorporation of arachidonic acid into platelets of drug-free patients with schizophrenia. Psychiatry Res 1996 28; 60: 11-21.
58. Gattaz WF, Schmitt A, Maras A. Increased platelet phospholipase A2 activity in schizophrenia. Schizophr Res 1995; 16: 1-6.
59. Gattaz WF, Brunner J, Schmitt A, Maras A. Accelerated breakdown of membrane phospholipids in schizophrenia--implications for the hypofrontality hypothesis. Fortschr Neurol Psychiatr 1994; 62: 489-496.
60. Das I, Essali MA, de Belleroche J, Hirsch SR. Inositol phospholipid turnover in platelets of schizophrenic patients. Prostaglandins Leukot Essent Fatty Acids 1992; 46: 65-6.
61. Mesa CS. Electron microscope studies of brain tissue in psychosis. Biol Psychiatry 1986; 5: 1092-1094.
62. Dickerson FB, Boronow JJ, Stallings C, Origoni AE, Ruslanova I, Yolken RH. Association of serum antibodies to herpes simplex virus I with cognitive deficits in individuals with schizophrenia. Arch Gen Psychiatry 2003; 60: 466-72.
63. Mesa CS. Esquizofrenia, plaquetas y virus herpes. Educational Material. Bulletin.Oct. 2003. World Psychiatric Association. http://www.wpanet.org/sectorial/edu14-3.html